Evofem Negotiates Improved Rebate for Hormone-Free “In the Moment” Contraceptive PHEXXI with Medi-Cal
— Medi-Cal serves more than 15.4 million Californians —
— 7.4% improvement in Phexxi rebate to take effect July 1, 2024 —
SAN DIEGO, March 20, 2024 /PRNewswire/ — Commercial-stage women’s health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program.